Amneal Expands Injectables Portfolio With Four Approvals

As Atroprine Receives CGT Status by the FDA

 
• By Akriti Seth

Amneal has announced the approval and launch of dexamethasone, azacitidine, carboprost and atropine in the US, as the company focuses on expanding its injectables portfolio with multiple launches to 2025.  

four launches
Amneal adds four approvals to its expanding generic injectables portfolio • Source: Alamy

More from Generics

More from Products